Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia

Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in genes encoding epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable, with few means to pred...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Meldi, Kristen, Qin, Tingting, Buchi, Francesca, Droin, Nathalie, Sotzen, Jason, Micol, Jean-Baptiste, Selimoglu-Buet, Dorothée, Masala, Erico, Allione, Bernardino, Gioia, Daniela, Poloni, Antonella, Lunghi, Monia, Solary, Eric, Abdel-Wahab, Omar, Santini, Valeria, Figueroa, Maria E.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2015
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4611703/
https://ncbi.nlm.nih.gov/pubmed/25822018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78752
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items